Prof Joseph Gligorov speaks to ecancer at the BGICC 2020 conference in Cairo, Egypt about adjuvant anti-HER2-positive treatment in HER2-positive breast cancer and what to do after a patient has received a pathologic complete response (pCR).

He explains that this is an ongoing debate, as there is no clinical trial addressing this issue, but believes that dual HER2 blockade with pertuzumab should still be continued if the patient has lymph node-positive disease.